drugset / Trial / NCT06782555
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Timeline
- Start
- 2025-01-08
- Primary completion
- 2027-10
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | — |
| Subject | Evofosfamide | Other / unclassified | — | — |
| Subject | Zalifrelimab | Monoclonal antibody | — | — |